Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
MAA | Ann: Removal from Trading Status - MAAT | 21/06/24 | 0 | 167 | |||
|
|||||||
MAA | Ann: Merger Implemented | 21/06/24 | 0 | 153 | |||
|
|||||||
MAA | Ann: Monash Merger Announcement (Exchange Ratio) | 14/06/24 | 0 | 168 | |||
|
|||||||
MAA | Ann: Suspension from Trading Status - MAAT | 13/06/24 | 0 | 178 | |||
|
|||||||
MAA | Ann: Results of Merger Meeting | 13/06/24 | 0 | 103 | |||
|
|||||||
MAA | Ann: Monthly Prime Brokerage Disclosure 31 May 2024 | 07/06/24 | 0 | 106 | |||
|
|||||||
MAA | Ann: Monthly Redemptions & Units on Issue 31 May 2024 | 07/06/24 | 0 | 93 | |||
|
|||||||
MAA | Ann: Update on Proposed Fund Merger | 05/06/24 | 0 | 152 | |||
|
See All Discussions
Timeline
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
View More |